<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02851277</url>
  </required_header>
  <id_info>
    <org_study_id>0892-CL-1001</org_study_id>
    <nct_id>NCT02851277</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine</brief_title>
  <official_title>A Phase 1, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA LAMP Vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of ASP0892 after
      intradermal or intramuscular injection in adults with peanut allergy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by number of participants with Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 576</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Vital sign: body temperature</measure>
    <time_frame>Up to Day 576</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Vital sign: blood pressure</measure>
    <time_frame>Up to Day 576</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Vital sign: pulse rate</measure>
    <time_frame>Up to Day 576</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by 12- lead Electrocardiograms (ECGs)</measure>
    <time_frame>Up to Day 576</time_frame>
    <description>The overall conclusion will be recorded as normal and abnormal (not clinically significant/ clinically significant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Laboratory test: hematology</measure>
    <time_frame>Up to Day 576</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Laboratory test: biochemistry</measure>
    <time_frame>Up to Day 576</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Laboratory test: urinalysis</measure>
    <time_frame>Up to Day 576</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Anti-Lysosomal associated membrane protein-1 (LAMP-1) antibody</measure>
    <time_frame>Up to Day 576</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>Low dose ASP0892 Intradermal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive study drug once every 2 weeks for a total of 4 doses. After participants complete the Low dose arms, the Dose Escalation Committee (DEC) will determine if the study can progress to the parallel higher dose arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose ASP0892 Intradermal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive study drug once every 2 weeks for a total of 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Intradermal</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose ASP0892 Intramuscular</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive study drug once every 2 weeks for a total of 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Intramuscular</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP0892 Intradermal</intervention_name>
    <description>Intradermal injection</description>
    <arm_group_label>High dose ASP0892 Intradermal</arm_group_label>
    <arm_group_label>Low dose ASP0892 Intradermal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP0892 Intramuscular</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>High dose ASP0892 Intramuscular</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Intradermal</intervention_name>
    <description>Intradermal injection</description>
    <arm_group_label>Placebo Intradermal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Intramuscular</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Placebo Intramuscular</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a body mass index (BMI) ≥ 18 and 32 at screening.

          -  Subject has a physician-diagnosed peanut allergy or history of peanut allergy.
             Subjects with history of nonsevere anaphylaxis (Grade ≤ 3) to peanuts (including mild
             wheezing or dyspnea without hypoxia) will be enrolled.

          -  Subject has an anti-Ara h2 IgE measured by ImmunoCAP &gt; 0.35 kU/L.

          -  Subject has a positive SPT to peanut with a change in wheal diameter ≥ 3 mm as
             compared to a negative control.

          -  Subject has a positive peanut double-blinded placebo-controlled food challenge
             (DBPCFC) at Screen 2 visit with an eliciting dose ≤ 300 mg peanut protein (≤ 444 mg
             cumulative reactive dose [CRD]).

          -  Female subject must either:

               -  Be of non-child bearing potential: post-menopausal (defined as at least 1 year
                  without any menses) prior to screening, or documented surgically sterile.

               -  Or, if of childbearing potential: Agree not to become pregnant during the study;
                  and have a negative (urine) pregnancy test result at screening and at day 1
                  (predose); and, if heterosexually active, agree to consistently use 2 forms of
                  highly effective birth control (at least one of which must be a barrier method)
                  starting at screening and throughout the study period.

          -  Female subject must agree not to breastfeed starting at screening and throughout the
             study period, and for 28 days after the final study drug administration.

          -  Female subject must not donate ova starting at screening and throughout the study
             period, and for 28 days after the final study drug administration.

          -  Male subject and female spouse/partners who are of childbearing potential must be
             using highly effective contraception consisting of two forms of birth control (at
             least one of which must be a barrier method) starting at screening and continue
             throughout the study period, and for 90 days after the final study drug
             administration.

          -  Male subject must not donate sperm starting at screening and throughout the study
             period, and for 90 days after the final study drug administration.

        Exclusion Criteria:

          -  Subject has severe anaphylaxis to peanuts (Grades 4 or 5 including dyspnea associated
             with hypoxia, cyanosis, hypotension, or neurological compromise) per the Grading of
             Food-Induced Anaphylaxis According to Severity of Clinical Symptoms based on
             historical clinical symptoms.

          -  Subject develops a Grade 4 or 5 reaction during the DBPCFC.

          -  Subject who has received or is planning to receive administration of any vaccine
             (other than injectable Influenza vaccine) within 28 days prior to the administration
             of the study vaccine or at any time during the study.

          -  Subject who received any specific immunotherapy for allergy (e.g., epicutaneous
             immunotherapy [EPIT], sublingual immunotherapy [SLIT], subcutaneous immunotherapy
             [SCIT], and oral immunotherapy [OIT]) during the past 12 months, currently, or plans
             to receive during the course of the study.

          -  Subject who has used the following drug(s) prior to the dosing of the study vaccine:

               -  Within 2 months prior to study vaccine administration: Systemic (or inhaled)
                  steroid, chemical mediator-isolation inhibitor, Th2 cytokine inhibitor,
                  thromboxane A2 synthesis inhibitor, thromboxane A2 receptor antagonist,
                  β-blocker, angiotensin-converting enzyme inhibitors, and/or angiotensin-receptor
                  blockers

               -  Within 3 months prior to study vaccine administration: Biologics and/or immune
                  modulators (including anti-TNFα antibody and anti-IgE monoclonal antibody)

          -  Subject who has history of allergic reactions such as anaphylactic shock, angioedema
             with airway constriction or hypotension caused by food other than peanut and/or
             medical products (including vaccine) in the past.

          -  Subject's laboratory test results at screening or prior to study vaccine dosing on day
             1 are outside the normal limits and considered to be clinically significant.

          -  Subject with anti-LAMP-1 antibodies above the cut-point for the Tier 1 assay and who
             is confirmed positive in the Tier 2 assay at Screen 1 visit (baseline).

          -  Subject who had a positive test results for hepatitis B surface (HBs) antigen,
             hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen/
             antibody.

          -  Subject who has immune disorders (including autoimmune disease) and/or diseases
             requiring immunosuppressive drugs.

          -  Subject who was diagnosed with immunodeficiency in the past.

          -  Subject who has uncontrolled hypertension.

          -  Subject who has a history of cardiovascular disease, arrhythmias, chronic lung
             disease, active eosinophilic gastrointestinal disease, or any other medical or
             surgical conditions which places the subject at increased risk for participation in
             the study.

          -  Subject who has a complication or medical history of respiratory disease which
             requires medical treatment.

          -  Subject who has a complication or medical history of malignant tumor.

          -  Subject who has mental conditions such as schizophrenia, bipolar disorder, and major
             depressive disorder, or a subject who has received drug(s) for the treatment of
             dementia.

          -  Subject who has severe or poorly controlled dermatitis atopic or generalized eczema.

          -  Subject who is unable to discontinue antihistamines within 7 days or 5 half-lives
             (whichever duration is longer) as follows:

               -  prior to dosing through 7 days post last dose of study vaccine

               -  prior to skin prick testing and oral food challenge procedures

          -  Subject who has asthma other than mild intermittent asthma (National Heart, Lung, and
             Blood Institute [NHLBI] guidelines) and has a FEV1 value &lt; 80% and/or requiring
             chronic maintenance treatment (i.e., inhaled corticosteroids).

          -  Subject who has already received vaccination of LAMP-vax such as ASP0892.

          -  Subject who has received investigational therapy within 35 days or 5 half- lives
             whichever is longer, prior to screening.

          -  Subject who is an employee of the Astellas Group or vendors involved in the study.

          -  Subject who has any condition which makes the subject unsuitable for study
             participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Astellas Pharma Global Development</last_name>
    <phone>800-888-7704</phone>
    <email>astellas.registration@astellas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site US10014</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US10008</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US10009</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US10001</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US10002</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US10004</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US10003</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US10012</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US10013</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US10006</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peanut Allergy</keyword>
  <keyword>ASP0892</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

